I've occasionally run across projects to develop better biomarkers for pre-eclampsia in pregnancy and for the risk of progression to eclampsia.
AHQR is running a 2022/2023 topic on the project. In March, they posted a project plan and took comment; the plan is still online.
https://effectivehealthcare.ahrq.gov/products/hypertensive-disorders-pregnancy/protocol
In November 2022, they posted a 76 page draft report with a 150 page appendix, and they are taking public comment til January 10, 2023.
Biomarkers are not a focus at all. Topics include (1) whether to use home blood pressure monitoring, (2) value of diuretics, (3) value of magnesium sulfate.
There are a couple very short passing remarks regarding biomarkers (to predict response to treatment, or, to predict seizures related to magnesium therapy, but blink and you'll miss these). See a recent LANCET article on, "Clinical tools and biomarkers to predict preeclampsia," McDonald et al, PMID 34954654, open access, here. Review articles like that apparently live on a different planet than the AHRQ scope of review.
I've put the half-dozen or so relevant documents in a cloud Zip file here.
